Multidisciplinary Care Program to Secure MEdication Therapy for HematoLOgy Patients Receiving Injectable Anticancer Drugs
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Chemotherapy Effect
- Sponsor
- Hospices Civils de Lyon
- Enrollment
- 38
- Locations
- 1
- Primary Endpoint
- Evaluation of the clinical impact of pharmacist interventions at first cycle of chemotherapy, according to the CLEO© scale.
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
Several experiences of multidisciplinary care pathways associating oncologists, pharmacists and nurses have been reported for cancer patients, with positive results on medication management safety, reduction of Drug-Related Problems (DRPs), and re-hospitalizations.
This study aims to evaluate the impact of a multidisciplinary city-hospital follow-up program on medication management safety in haematological oncology patients receiving intravenous chemotherapy in onco-haematology. Additional aspects will be evaluated, such as the impact of the follow-up on the city-hospital link, satisfaction of patients and professionals involved in the follow-up and the use of telecare
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adult patients aged 18 years or older With hematological malignancy at any stage Initiating R-CHOP or G-CHOP chemotherapy Who do not object to participation in the study and use of collected data
Exclusion Criteria
- •Patients already enrolled in a clinical trial evaluating any drug product
- •Patients living in an institution
- •Patients protected by law
- •Adults subject to a legal protection measure (curatorship, guardianship) (article L1121-8 of the CSP)
- •Persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care and persons admitted to a health or social establishment (article L1121-6 of the CSP)
Outcomes
Primary Outcomes
Evaluation of the clinical impact of pharmacist interventions at first cycle of chemotherapy, according to the CLEO© scale.
Time Frame: 6 months after inclusion
Each pharmacist intervention performed during patient follow-up will be rated according to its expected level of clinic impact (major, moderate, minor, null)